The formation of senile plaques followed by deposition of amyloid b peptides (Ab) are the earliest pathological changes of Alzheimer's disease (AD); thus, detection of the plaques remains the most important early diagnostic indicator of AD. Amyloid imaging is a noninvasive technique for visualizing senile plaques in the brains of patients with Alzheimer's using positron emission tomography (PET) or magnetic resonance (MR) imaging. Several types of probes have been developed for PET, but few ligands have been developed speciˆcally for MR imaging detection of amyloid plaques. This review presents recent advances in amyloid imaging using MR imaging and includes our studies.
Introduction
Alzheimer's disease (AD) is a cognitive impairment disorder characterized by cerebral atrophy, deposits of amyloid b peptide (Ab), neuroˆbrillary tangles, and neuronal cell loss. According to the amyloid cascade hypothesis for AD, formation of senile plaques followed by the deposition of Ab are the earliest pathological changes of AD. 1, 2 Detection of senile plaques is therefore the most important indicator for early diagnosis of AD.
Amyloid imaging is a noninvasive technique that uses positron emission tomography (PET) or magnetic resonance (MR) imaging to visualize Ab plaques in the brain. With the increasing incidence of AD as the average age of many populations increases, amyloid imaging has attracted increasing attention for the early diagnosis of AD. Representative ligands for PET, such as N-methyl-[ 11 C]2-(4-mmethylaminophenyl)-6-hydroxybenzothiazole (PIB) 3 and 2-[2-(2-dimethylaminothiazol-5-yl) ethenyl]-6-[2-(‰uoro)ethoxy] benzoxazole (BF-227), 4 have been used in clinical research, but no clinical studies of amyloid imaging using MR imaging have been conducted. The likely bottleneck is the lower sensitivity of MR imaging than PET. Many researchers are thus trying to develop novel contrast agents (Table) and pulse sequences 5 to increase the sensitivity of amyloid detection. We review the trend in amyloid imaging using MR imaging and include results from our studies.
Amyloid Imaging without Contrast Agents
Senile plaques in the brains of patients with AD contain iron and iron-binding proteins, such as lactotransferrin and melanotransferrin, 6, 7 and so appear as areas of low density by MR imaging using T 2 *-weighted gradient echo 8 and T 2 -weighted spin echo sequences 9,10 at high magneticˆelds. However, the many hours to obtain a complete image of the senile plaques preclude such studies for in vivo imaging. Amyloid imaging without contrast agents is the ideal alternative, although additional research is needed before applying this approach in human patients. Recently, Chamberlain and colleagues 5 reported on amyloid plaque contrast generated by a novel imaging method called susceptibility-weighted imaging (SWI). Their ex vivo study presented important observations for the future of in vivo MR imaging of amyloid.
Amyloid Imaging with Contrast Agents
The essential characteristics of contrast agents Abbreviations and acronyms FSB: (E,E)-1-‰uoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene, Gd-DOTA; gadolinium-tetraazacyclododecanetetraacetic acid, Gd-DTPA: gadopentetate dimeglumine, MION: monocrystalline iron oxide nanoparticles PUT: putrescine, TFMB: tri‰uorometh-oxy-benzylate. 
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for amyloid imaging are binding a‹nity, capacity to pass through the blood-brain barrier (BBB), nontoxicity, and strong signal intensity in the brain. In general, amyloid-binding compound derivatives and paramagnetic-labeled compounds are used.
Gadolinum-labeled contrast agents
Gadolinium (Gd) is a typical contrast agent used for MR imaging. Gd-labeled Ab peptide [11] [12] [13] and Ab antibody 14 have been injected into transgenic mice with AD to detect amyloid plaques in the mouse brain. Using high magneticˆeld MR systems, senile plaques in the mouse brain are visualized with T 1 -weighted and T 2 -weighted MR images as the high and low signal intensities, respectively. The above results suggested that amyloid plaque might also be detected using other magnetically labeled Ab peptide and Ab antibody, such as monocrystalline iron oxide nanoparticle (MION)-Ab1-40. 12 
19 F-labeled contrast agents
The advantage of 19 F-MR imaging is the high sensitivity of the 19 F to MR ratio ( 1 H: 19 F＝1: 0.83), high natural abundance ratio (100z), and absence of endogenous 19 F. However, disadvantages to amyloid imaging by 19 F-MR imaging include the low concentration accumulated in the body and the lack of clarity regarding chemical properties of probes that improve amyloid detection.
(E,E)-1-‰uoro-2,5-bis(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (FSB) (Fig. 1a) , 15 bis-styrylbenzenes (Fig. 1b, c) , 16 and tri‰uoromethoxy-benzylated (TFMB) compounds (Fig. 1d, e) 17 have been reported as amyloid imaging ligands for 19 F-MR imaging. FSB allowed the detection of Ab plaques in transgenic mice with amyloid precursor protein (APP) using 9.4-tesla MR imaging, 15 but we could not detect the 19 F-signal of injected FSB (200 mg/head) in mouse brain at 7T. We therefore investigated developing novel 19 F-labeled amyloidimaging ligands for MR imaging and improved instrumentation.
First, we synthesized 2-(4'-dimethylaminostyryl)-6-s 2-[(3'-tri‰uoromethoxy)benzylamino] ethoxyethoxyt benzoxazole (TFMB-2Et) and 2-(4'-dimethylaminostyryl)-6-s 2-[(3'-tri‰uoromethoxy) benzylamino]ethoxyethoxyethoxyt benzoxazole (TFMB3Et), both of which have stronger 19 F-signals than FSB. We attempted to localize TFMB-2Et and TFMB-3Et in mouse muscle and brain using 7T MR imaging, but detecting 19 F-signal in mouse brain was di‹cult. 17 Ex vivo MR imaging and in vitro nuclear magnetic resonance (NMR) analyses showed the NMR signals of 19 F to be very sensitive to the tissue environment and that brain tissues inhibit amyloid detection in 19 F-MR imaging by aŠecting the 19 F-NMR signals. 17 Comparing the log P values and the intensities of 19 F-NMR signals in brain homogenates using several compounds with a tri‰uoro-base revealed that hydrophilic chemicals (low log P) have relatively strong 19 F-NMR signals. Therefore, eŠective MR imaging of amyloid in the brain requires optimizing probe hydrophilicity while retaining good brain permeability of the probe.
Second, we optimized the radiofrequency (RF) coil because we detected an unexpectedly high 19 F signal with our home-built, solenoid-type volume coil designed to detect the 19 F signal of TFMB-2Et ( Fig. 2A) . The 19 F chemical shift image of a TFMB2Et tube in 3 orthogonal planes with a largerˆeld of view showed 19 F-signal of the TFMB-2Et (Fig.  3D-I , arrow) and additional high signal from the capacitors (Fig. 3 D-I, arrowhead) . We successfully removed the noise by replacing the existing capacitor with glass parts (Fig. 2B) . Attention should also be paid to instrument noise in detecting weak 19 F signals.
Amyloid Imaging by Cell Tracking
Because microglia accumulate around senile plaques and remove Ab deposits in the brain, 18 we could track microglia around senile plaques by MR imaging. Because native cells are not detected by MR imaging, cells must be labeled with a contrast agent for MR tracking. The most popular such agents are superparamagnetic iron oxides (SPIOs). We 19 and others 20 have developed a highly e‹cient labeling method using a nonviral vector system, the hemagglutinating virus of Japan (HVJ; Sendai virus) envelope (HVJ-E) vector. The high eŠective-ness of HVJ-E vector labeling allowed us to detect a few cells at each spot in the mouse brain using MR imaging. 21 We then injected b-amyloid peptide Ab1-42 (Ab42) into the left hippocampus and saline into the right hippocampus of rats and labeled microglia with a SPIO (Resovist, Bayer, Osaka, Japan) administered via the carotid artery or lateral ventricle. MR imaging revealed clear signal changes attributable to Resovist-containing microglia accumulated in the areas injected with Ab42. 22, 23 Because microglia accelerate the removal of Ab, this technique might also be applicable to amyloid imaging and cell therapy for AD.
Conclusion
Although many researchers have addressed the development of novel contrast agents and pulse sequence to increase the sensitivity of amyloid detection, many issues still exist in using amyloid imaging for MR imaging in humans. However, such application of MR imaging is very useful in terms of safety, cost, and apparatus penetration rate and is expected to progress in the future. 
